language_icon
EN
HI

Sai Life Sciences Share price

SAILIFE

1006

47.35 (4.94%)
NSE
BSE
Last updated on 22 Apr, 2026 | 15:48 IST
Today's High

1014.80

Today's Low

955.60

52 Week Low

675.40

52 Week High

1084.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Sai Life Sciences Chart

Sai Life Sciences Share Key Metrics

Volume
7.94 L
Market Cap
21303.87 CR
LTQ@LTP
5@1006.00
ATP
995.39
Var Margin
17.76 %
Circuit Range
766.95-1150.35
Delivery %
64.51 %
Value
79.00 CR
ASM/GSM
No
Market Lot
1

Summary

Sai Life Sciences share price stands at ₹1006 at 22 Apr, 2026 | 15:48. The stock Sai Life Sciences intraday movement has stayed between ₹955.60 and ₹1014.80, while on a 52-week basis it has fluctuated from ₹675.40 to ₹1084.00.
In terms of trading activity, Sai Life Sciences has recorded a volume of 793658 shares. The Sai Life Sciences has a market cap of ₹211768134. The stock’s Average Traded Price (ATP) stands at ₹99539, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 5, 100600.
The Sai Life Sciences operates within a circuit range of ₹766.95-1150.35 – ₹766.95-1150.35, with a Value of ₹79.00 CR. The Delivery Percentage for the day is 64.51%. Additionally, Sai Life Sciences currently falls under the No framework, and trades with a market lot size of 1.

Sai Life Sciences Fundamentals

View More
P/E Ratio

60.96

P/B Ratio

8.56

Div. Yield

0

Sector P/E

63.84

Sector P/B

3.48

Sec. Div. Yield

0.57

Sai Life Sciences Resistance and Support

Pivot 959.92

Resistance

First Resistance

975.84

Second Resistance

993.02

Third Resistance

1008.94

Support

First Support

942.74

Second Support

926.82

Third Support

909.64

Sai Life Sciences Shareholding Pattern

View More
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

34.61%

Mutual Fund

27.8%

Insurance

3.07%

Foreign Institutional Investors

21.17%

Domestic Institutional Investors

0.67%

Retail

12.68%

Others

0%

Total Promoters
MAR '26
34.61%

Sai Life Sciences Corporate Actions

DateAgenda
2026-02-05Quarterly Results
2025-11-06Quarterly Results
2025-08-07Quarterly Results
2025-05-13Audited Results
2025-02-06Quarterly Results

Sai Life Sciences News

Sai Life Sciences Limited

SAI LIFE SCIENCES board to meet on May 14, 2026, to consider and approve audited standalone and consolidated financial results for FY26. The meeting will review the company's full-year performance.
Apr 21 2026 14:04:00

Sai Life Sciences Ltd - 544306 - Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone & Consolidated) For The Fourth Quarter And Year Ended 31 March 2026.

Sai Life Sciences board to meet on May 14, 2026, to approve audited Q4 and FY26 financial results. The trading window has been closed since April 1, 2026, and will reopen 48 hours after results declaration.
Apr 21 2026 13:04:00

Sai Life Sciences Limited

SAI Life Sciences appointed Dr. John Pavey as a senior leader in CMC and chemical development, effective April 1, 2026. He brings over two decades of global experience from pharmaceutical giants like Johnson & Johnson. This change follows the retirement of Dr. Dean David Edney on March 31, 2026.
Apr 01 2026 10:04:00

Sai Life Sciences Limited

SAI Life Sciences appointed Dr. John Pavey as a senior leader in CMC and chemical development, effective April 1, 2026. He brings over two decades of global experience from pharmaceutical giants like Johnson & Johnson. This change follows the retirement of Dr. Dean David Edney on March 31, 2026.
Apr 01 2026 10:04:00

Sai Life Sciences Limited

Sai Life Sciences appointed Dr. John Pavey as Head – Global PR&D and Senior Management Personnel, effective April 1, 2026, succeeding Dr. Dean David Edney. Dr. Pavey brings over two decades of global experience in CMC and chemical development.
Mar 30 2026 22:03:00

Sai Life Sciences Ltd - 544306 - Announcement under Regulation 30 (LODR)-Change in Management

Sai Life Sciences appointed Dr. John Pavey as Senior Management Personnel (SMP), Head – Global PR&D, effective April 1, 2026. He brings over two decades of global experience in CMC and chemical development.
Mar 30 2026 22:03:00
Read More

About Sai Life Sciences

NSE : 27839  
BSE : 544306  
ISIN : INE570L01029  

Our Company was originally incorporated as ‘Sai Dru Syn Laboratories Limited’ at Hyderabad Telangana (erstwhile Andhra Pradesh) as a public limited company under the Companies Act 1956 pursuant to a certificate of incorporation dated January 25 1999 issued by the Registrar of Companies Andhra Pradesh at Hyderabad. Our Company received the certificate of commencement of business from Registrar of Companies Andhra Pradesh at Hyderabad on February 17 1999. Subsequently the name of our Company was changed from ‘Sai Dru Syn Laboratories Limited’ to ‘Sai Life Sciences Limited’ pursuant to a Shareholders’ resolution in an extraordinary general meeting held on December 11 2003 and a fresh certificate of incorporation dated December 16 2003 consequent to change of name was issued by the Registrar of Companies Andhra Pradesh at Hyderabad. Thereafter the name of the Company was changed from ‘Sai Life Sciences Limited’ to ‘Sai Advantium Pharma Limited’ pursuant to a Shareholders’ resolution in an extraordinary general meeting held on August 16 2006 and a fresh certificate of incorporation dated August 30 2006 consequent to change of name was issued by the Registrar of Companies Andhra Pradesh at Hyderabad. Subsequently the name of our Company was changed from ‘Sai Advantium Pharma Limited’ to its present name ‘Sai Life Sciences Limited’ pursuant to a Shareholders’ resolution in an extraordinary general meeting held on April 20 2012 and a fresh certificate of incorporation dated May 28 2012 consequent to change of name was issued by the Registrar of Companies Andhra Pradesh at Hyderabad.Major Events and Milestones:1999- Incorporation of our Company2002- Inauguration of our R&D labs in ICICI Knowledge Park Hyderabad.2004- Strategic acquisitions of Prasad Drugs Limited the current Unit III Bolarum Facility2006- Investment by Advantium LLC in our Company to set-up discovery services to expand our Company’s business.- Acquired Merrifield Pharma Private Limited2007- Acquisition of shares of our Company held by Advantium LLC by Sequoia Capital India Investments III2008- Investment by MPM Investment Mauritius in our Company2014- Acquisition of shares of our Company held by MPM Investment Mauritius and Sequoia Capital India Investment III by Tata Capital Healthcare Fund 12016- Acquisition of shares of our Company held by MPM Investment Mauritius by HBM Private Equity India and subscription to shares of our Company2019- Opened biology facility in Watertown (Greater Boston MA) U.S.A2020- Launched Sai Nxt an initiative aiming to transform the organization into a new generation CDMO- Addition of cellular analysis platforms at our discovery biology facility in Cambridge Massachusetts USA2021- Opened new 75000 sq. ft. discovery biology facility at our integrated R&D campus at Unit II Hyderabad Facility2022- Inauguration of the first set of new discovery chemistry labs as part of the new integrated discovery block at Unit II Hyderabad Facility- Announced the launch of BIOVIA Electronic Lab Notebook application2023- Inauguration of high potency API manufacturing block at Unit IV Bidar Facility.2024- Initiated API developability & formulations (D&F) capabilities at Unit II Hyderabad

Read More

Sai Life Sciences Management

NamePosition
Runa KaranCompany Secretary & Compliance Officer
Kanumuri Ranga RajuChairman
View More

Sai Life Sciences FAQs

The Buying Price of Sai Life Sciences share is 1006 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Sai Life Sciences stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Sai Life Sciences, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Sai Life Sciences shares is 60.96. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Sai Life Sciences shares is 8.56. Useful to assess the stock's value relative to its book value.

To assess Sai Life Sciences’s valuation compare Sector P/E, P/B which are 63.84 & 3.48 with sector averages, along with growth rates and financial metrics.

The Market Cap of Sai Life Sciences is 21303.87 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Sai Life Sciences share price is 1084.00 & 675.40. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Sai Life Sciences belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost